"Antigens, CD34" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Glycoproteins found on immature hematopoietic cells and endothelial cells. They are the only molecules to date whose expression within the blood system is restricted to a small number of progenitor cells in the bone marrow.
| Descriptor ID |
D018952
|
| MeSH Number(s) |
D23.050.301.264.035.134 D23.101.100.110.134
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antigens, CD34".
Below are MeSH descriptors whose meaning is more specific than "Antigens, CD34".
This graph shows the total number of publications written about "Antigens, CD34" by people in this website by year, and whether "Antigens, CD34" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1994 | 0 | 1 | 1 |
| 1996 | 0 | 1 | 1 |
| 1998 | 1 | 2 | 3 |
| 2000 | 1 | 0 | 1 |
| 2001 | 0 | 1 | 1 |
| 2007 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 1 | 0 | 1 |
| 2016 | 3 | 0 | 3 |
| 2018 | 0 | 2 | 2 |
| 2020 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antigens, CD34" by people in Profiles.
-
Superficial CD34-Positive Fibroblastic Tumor. Int J Surg Pathol. 2020 Dec; 28(8):879-881.
-
Functional Inhibitory Siglec-6 Is Upregulated in Human Colorectal Cancer-Associated Mast Cells. Front Immunol. 2018; 9:2138.
-
Autologous CD34+ cell therapy improves exercise capacity, angina frequency and reduces mortality in no-option refractory angina: a patient-level pooled analysis of randomized double-blinded trials. Eur Heart J. 2018 06 14; 39(23):2208-2216.
-
PreSERVE-AMI: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial of Intracoronary Administration of Autologous CD34+ Cells in Patients With Left Ventricular Dysfunction Post STEMI. Circ Res. 2017 Jan 20; 120(2):324-331.
-
The RENEW Trial: Efficacy and Safety of Intramyocardial Autologous CD34(+) Cell Administration in Patients With Refractory Angina. JACC Cardiovasc Interv. 2016 08 08; 9(15):1576-85.
-
Autologous CD34+ Cell Therapy for Refractory Angina: 2-Year Outcomes From the ACT34-CMI Study. Cell Transplant. 2016; 25(9):1701-1711.
-
Human uterine leiomyoma stem/progenitor cells expressing CD34 and CD49b initiate tumors in vivo. J Clin Endocrinol Metab. 2015 Apr; 100(4):E601-6.
-
Race and ethnicity influences collection of granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells from unrelated donors, a Center for International Blood and Marrow Transplant Research analysis. Biol Blood Marrow Transplant. 2015 Jan; 21(1):165-71.
-
A phase 3, randomized, double-blinded, active-controlled, unblinded standard of care study assessing the efficacy and safety of intramyocardial autologous CD34+ cell administration in patients with refractory angina: design of the RENEW study. Am Heart J. 2013 Jun; 165(6):854-861.e2.
-
Assessment of safety, accuracy, and human CD34+ cell retention after intramyocardial injections with a helical needle catheter in a porcine model. Catheter Cardiovasc Interv. 2013 May; 81(6):970-7.